CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cardoz AB
ClinicalTrials.gov Identifier:
NCT01540604
First received: February 23, 2012
Last updated: October 1, 2012
Last verified: October 2012
  Purpose

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.


Condition Intervention Phase
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Drug: CRD007
Phase 2

Study Type: Interventional
Official Title: An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD

Resource links provided by NLM:


Further study details as provided by Cardoz AB:

Arms Assigned Interventions
Experimental: CRD007 10 mg tablet Drug: CRD007

  Eligibility

Ages Eligible for Study:   2 Years to 11 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Documented diagnosis of dystrophinopathy

Exclusion Criteria:

  • Severe functional impairment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01540604

Locations
Sweden
Stockholm, Sweden
Sponsors and Collaborators
Cardoz AB
Investigators
Principal Investigator: T Sejersen, MD PhD Karolinska University Hospital
  More Information

No publications provided

Responsible Party: Cardoz AB
ClinicalTrials.gov Identifier: NCT01540604     History of Changes
Other Study ID Numbers: Cardoz-004
Study First Received: February 23, 2012
Last Updated: October 1, 2012
Health Authority: Sweden: Medical Products Agency

Keywords provided by Cardoz AB:
DMD
BMD
symptomatic carriers

Additional relevant MeSH terms:
Muscular Dystrophy, Duchenne
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on April 16, 2014